Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium, Showcasing Advances in Breast Cancer Risk Assessment and Treatment
A featured discussion sheds light on how the Combined Risk Score can lead to better breast cancer prevention and screening strategies. SALT LAKE CITY, Nov. 29, 2022 (GLOBE NEWSWIRE) — Myriad Genetics, Inc.., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced several new data presentations at the San Antonio Breast Cancer …